Optinose, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OPTN
Optinose, INC10-Q: OptiNose Reports Q1 2025 Results, Highlights XHANCE Growth Amidst Merger Agreement with Paratek
OptiNose, Inc. announces its first quarter 2025 financial results, showcasing increased XHANCE prescriptions and revenue per prescription, while also addressing liquidity concerns and an impending merger with Paratek Pharmaceuticals.
OPTN
Optinose, INCOptiNose's Q3 2024 results show a slight revenue increase, driven by changes to their co-pay program, despite a decrease in overall prescriptions.
OPTN
Optinose, INC10-Q: OptiNose Reports Second Quarter 2024 Results, Revenue Increases Despite Prescription Volume Decline
OptiNose's Q2 2024 revenue increased due to higher net revenue per prescription, despite a decrease in overall prescription volume.
OPTN
Optinose, INCOptiNose, Inc. reported a 25% increase in net product revenue for the first quarter of 2024, driven by higher average revenue per prescription, despite a decrease in overall prescription volume.